Advancing human metapneumovirus vaccine development through fusion protein stabilization

Area of Science:

• Virology
• Immunology
• Structural Biology

Background:

• Human metapneumovirus (hMPV) is a significant respiratory pathogen causing global disease, especially in vulnerable populations.
• Current unmet medical need exists due to the lack of licensed hMPV vaccines or antiviral therapies.
• The hMPV fusion (F) glycoprotein is a primary target for therapeutic and vaccine development.

Purpose of the Study:

• To review structure-guided strategies for stabilizing the hMPV F glycoprotein in its prefusion conformation.
• To synthesize preclinical immunogenicity data for hMPV vaccine candidates.
• To discuss implications for rational vaccine and immunotherapeutic design against hMPV.

Main Methods:

• Structure-guided protein engineering techniques to stabilize the prefusion conformation of hMPV F glycoprotein.
• Analysis of various stabilization strategies including proline substitutions, disulfide bonds, cavity filling, and scaffolds.
• Review of preclinical immunogenicity data from animal models.

Main Results:

• Several structure-guided strategies effectively stabilize the hMPV F glycoprotein in the prefusion conformation.
• Preclinical studies demonstrate the immunogenicity of stabilized prefusion F antigens.
• Advances in stabilization techniques and immunogenicity data provide a foundation for vaccine development.

Conclusions:

• Stabilizing the hMPV F glycoprotein in the prefusion state is critical for eliciting potent neutralizing antibodies.
• Recent structure-guided approaches show promise for developing effective hMPV vaccines.
• Leveraging insights from RSV vaccine development can accelerate hMPV therapeutic strategies.